Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211083640> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3211083640 endingPage "662" @default.
- W3211083640 startingPage "655" @default.
- W3211083640 abstract "The purpose was to explore the safety of different doses of ulinastatin combined with remifentanilin the treatment of severe sepsis in ICUand to analyze their effect on survival rate and organ function of patients. Methods. 57 patients with severe sepsis in ICU admitted to our hospital (2018.1.1-2021.6.30) were selected as the research subjects, and randomly divided into control group (28 cases) and experimental group (29 cases). The control group was treated with conventional dose of ulinastatin combined with remifentanil, while the experimental group was treated with high dose of ulinastatin combined with remifentanil to compare and analyze the treatment safety, organ function and survival rate in the two groups.Results. After treatment, the APACHE-II scores of both groups were lower than those before treatment, and the APACHE-II score in the experimental group was lower than that in the control group (P < 0.05). There were statistically significant differences in ventilator supporting time and ICU stay time between the two groups after treatment (P < 0.05). The expression levels of inflammatory factors in the experimental group were lower than those in the control group after treatment (P < 0.05). The lung function and PICCO indexes in the experimental group were better than those in the control group after treatment (P < 0.05). The peripheral blood CD4+, CD8+, CD4+/CD8+ and 28-day survival rate in the experimental group were higher than those in the control group (P < 0.05). No adverse drug reactions such as sudden vomiting, dyspnea and rash occurred in the two groups during the treatment. Conclusion. High-dose ulinastatin combined with remifentanilhas good therapeutic effect on severe sepsis in ICU. Compared with conventional dose, high-dose ulinastatin can effectively protect the body’s immune regulation, restore organ function and significantly improve the 28-day survival rate of patients, with medicationsafety, which has high value of clinical application and promotion." @default.
- W3211083640 created "2021-11-08" @default.
- W3211083640 creator A5024455727 @default.
- W3211083640 creator A5027475930 @default.
- W3211083640 creator A5041857421 @default.
- W3211083640 creator A5063177364 @default.
- W3211083640 creator A5063459637 @default.
- W3211083640 date "2021-07-31" @default.
- W3211083640 modified "2023-09-24" @default.
- W3211083640 title "Safety of Different Doses of Ulinastatin Combined with Remifentanilin the Treatment of Severe Sepsis in ICU and Their effect on Survival Rate and Organ Function of Patients" @default.
- W3211083640 hasPublicationYear "2021" @default.
- W3211083640 type Work @default.
- W3211083640 sameAs 3211083640 @default.
- W3211083640 citedByCount "0" @default.
- W3211083640 crossrefType "journal-article" @default.
- W3211083640 hasAuthorship W3211083640A5024455727 @default.
- W3211083640 hasAuthorship W3211083640A5027475930 @default.
- W3211083640 hasAuthorship W3211083640A5041857421 @default.
- W3211083640 hasAuthorship W3211083640A5063177364 @default.
- W3211083640 hasAuthorship W3211083640A5063459637 @default.
- W3211083640 hasConcept C126322002 @default.
- W3211083640 hasConcept C141071460 @default.
- W3211083640 hasConcept C197934379 @default.
- W3211083640 hasConcept C2778384902 @default.
- W3211083640 hasConcept C2778426790 @default.
- W3211083640 hasConcept C2778570526 @default.
- W3211083640 hasConcept C2780852908 @default.
- W3211083640 hasConcept C2781246285 @default.
- W3211083640 hasConcept C42219234 @default.
- W3211083640 hasConcept C71924100 @default.
- W3211083640 hasConcept C90924648 @default.
- W3211083640 hasConceptScore W3211083640C126322002 @default.
- W3211083640 hasConceptScore W3211083640C141071460 @default.
- W3211083640 hasConceptScore W3211083640C197934379 @default.
- W3211083640 hasConceptScore W3211083640C2778384902 @default.
- W3211083640 hasConceptScore W3211083640C2778426790 @default.
- W3211083640 hasConceptScore W3211083640C2778570526 @default.
- W3211083640 hasConceptScore W3211083640C2780852908 @default.
- W3211083640 hasConceptScore W3211083640C2781246285 @default.
- W3211083640 hasConceptScore W3211083640C42219234 @default.
- W3211083640 hasConceptScore W3211083640C71924100 @default.
- W3211083640 hasConceptScore W3211083640C90924648 @default.
- W3211083640 hasLocation W32110836401 @default.
- W3211083640 hasOpenAccess W3211083640 @default.
- W3211083640 hasPrimaryLocation W32110836401 @default.
- W3211083640 hasRelatedWork W1843830281 @default.
- W3211083640 hasRelatedWork W2350218610 @default.
- W3211083640 hasRelatedWork W2351619469 @default.
- W3211083640 hasRelatedWork W2358640039 @default.
- W3211083640 hasRelatedWork W2359662301 @default.
- W3211083640 hasRelatedWork W2361284659 @default.
- W3211083640 hasRelatedWork W2363617783 @default.
- W3211083640 hasRelatedWork W2366798769 @default.
- W3211083640 hasRelatedWork W2378573546 @default.
- W3211083640 hasRelatedWork W2387126446 @default.
- W3211083640 hasRelatedWork W2387188464 @default.
- W3211083640 hasRelatedWork W2387705920 @default.
- W3211083640 hasRelatedWork W2391587471 @default.
- W3211083640 hasRelatedWork W2416216772 @default.
- W3211083640 hasRelatedWork W2800029275 @default.
- W3211083640 hasRelatedWork W3031717502 @default.
- W3211083640 hasRelatedWork W3032160080 @default.
- W3211083640 hasRelatedWork W3032491831 @default.
- W3211083640 hasRelatedWork W3136608440 @default.
- W3211083640 hasRelatedWork W2356910784 @default.
- W3211083640 isParatext "false" @default.
- W3211083640 isRetracted "false" @default.
- W3211083640 magId "3211083640" @default.
- W3211083640 workType "article" @default.